e-ISSN: 2617-7668     print ISSN: 2522-9176
Русский Azərbaycanca
Our experience with bevacizumab treatment in breast cancer
##common.pageHeaderLogo.altText## EURASIAN JOURNAL OF CLINICAL SCIENCES
Vol. 4 No. 1 (2022)
Conference Abstract Book

Our experience with bevacizumab treatment in breast cancer

Published: November 28, 2022
DOI: https://doi.org/10.28942/ejcs.v4i1.109

Abstract

Evaluation and comparative analysis of the results of standard chemotherapy combined with vascular endothelial growth factor A (VEGF-A) inhibitor bevacizumab (KDM+beva) and standard chemotherapy (KDM) without bevacizumab in breast cancer (SVX).

References

www.ejcs.org

PDF (Azərbaycanca)
PDF (Azərbaycanca)

Keywords

Breast cancer
chemotherapy
relapse Рак молочной железы
химиотерапия
рецидив Süd vəzi xərçəngi
kimyəvi dərman müalicə
residiv
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.